Neurofilament Levels Linked to AF Risk
Higher levels associated with stroke, death, and heart failure in long-term cohort
-
By
-
Andrea Surnit
-
March 30, 2026
-
Clinical Scorecard: Neurofilament Levels Linked to AF Risk
At a Glance
| Category | Detail |
|---|
| Condition | Atrial Fibrillation (AF) |
| Key Mechanisms | Higher serum neurofilament light chain (NfL) levels linked to increased risk of major vascular events and mortality. |
| Target Population | Patients with atrial fibrillation, particularly those not receiving anticoagulation. |
| Care Setting | Multicenter observational study in Switzerland. |
Key Highlights
- Each doubling of serum NfL levels associated with a 35% higher risk of major vascular events.
- Major vascular event incidence rose from 14% in the lowest NfL quartile to 55% in the highest.
- NfL levels linked to increased risks of nonfatal stroke, cardiovascular death, heart failure hospitalization, and all-cause mortality.
- Stronger associations observed in patients not on anticoagulation and those without prior stroke or TIA.
- NfL may serve as a noncardiac biomarker for identifying high-risk AF patients.
Guideline-Based Recommendations
Diagnosis
- Measure serum NfL levels in patients with AF to assess risk.
Management
- Consider monitoring NfL levels for risk stratification in AF patients.
Monitoring & Follow-up
- Regular follow-up of NfL levels may help in predicting major vascular events.
Risks
- Increased risk of cardiovascular death, stroke, and heart failure-related hospitalization with higher NfL levels.
Patient & Prescribing Data
Patients with atrial fibrillation enrolled in a cohort study.
Higher NfL levels indicate a need for closer monitoring and potential intervention.
Clinical Best Practices
- Incorporate NfL level assessment into routine evaluations for AF patients.
- Utilize NfL levels to enhance the ABC-AF risk score for better prediction of outcomes.
References
